About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.

A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)

Clinicaltrials.gov identifier NCT03923140

Recruitment Status Recruiting

First Posted April 22, 2019

Last update posted June 4, 2019

Study Description

Brief summary:

This is a prospective cohort study to observe the efficacy and safety of tranilast in CAPS patients. The investigators would analyze the changes in Auto-Inflammatory Diseases Activity Index (AIDAI) before and after treatment as well as changes in inflammatory markers, patients' and physician's global assessment of disease activity to determine the efficacy and safety of tranilast.

  • Condition or Disease:Cryopyrin-Associated Periodic Syndromes
  • Intervention/Treatment: Drug: Tranilast
  • Phase: Phase 2
Detailed Description

Seventy-one patients with CAPS will be recruited. After signing the informed consent, they will be administrated with tranilast (For juvenile patients, 5mg/kg.d with a maximum dose of 0.3g per day; For adult patients, the dose is 0.1g each time, three times a day). These patients will be followed up for 6 months. AIDAI is recorded by patients' or their parents one month before the start of treatment, and at the 1st, 3rd and 6th month after the treatment. Inflammatory markers, and patients' and physician's global assessment of disease activity will be assessed during the 1st, 3rd and 6th month follow-up. Side effects will be monitored and recorded as well. Experimental data before and after the administration of tranilast will be analyzed and be statistically processed, to figure out whether tranilast is effective and safe for CAPS patients.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 71 participants
  • Intervention Model: Single Group Assignment
  • Intervention Model Description: a single-arm prospective cohort study
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Efficacy and Safety of Tranilast in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS): A Single-Arm Prospective Cohort Study
  • Actual Study Start Date: May 2019
  • Estimated Primary Completion Date: April 2024
  • Estimated Study Completion Date: October 2024
Arms and interventions
Arm Intervention/treatment
Experimental: Tranilast
5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
Drug: Tranilast
5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
Outcome Measures
  • Primary Outcome Measures: 1. Changes in Auto-Inflammatory Diseases Activity Index score after 6-month treatment over baseline [ Time Frame: The previous 1 month before treatment and the 6th month after treatment ]
    Patients or their parents completed a 1-month (31 days) prospective diary with 12 yes/no items( Fever ≥38°C, Overall symptoms, Abdominal pain, Nausea/vomiting, Diarrhoea, Headaches, Chest pain, Painful nodes, Arthralgia or myalgia, Swelling of the joints, Eye manifestations, Skin rash) at the previous 1 month before treatment, and the 6th month after treatment . Each item of this diary was dichotomised as no (0)=absence of symptom or yes (1)=presence of symptom. The calculation of the Auto-Inflammatory Diseases Activity Index score is straightforward, consisting of the sum of all 12 items (0-372 in a month of 31 days). Higher values represent higher disease activity.
  • Secondary Outcome Measures: 1. Changes in Auto-Inflammatory Diseases Activity Index score at the 1st and 3rd month over baseline [ Time Frame: The previous 1 month before treatment and the 1st and 3rd month after treatment ]
    Patients or their parents completed a 1-month (31 days) prospective diary with 12 yes/no items( Fever ≥38°C, Overall symptoms, Abdominal pain, Nausea/vomiting, Diarrhoea, Headaches, Chest pain, Painful nodes, Arthralgia or myalgia, Swelling of the joints, Eye manifestations, Skin rash) at the previous 1 month before treatment, and the 1st and 3rd month after treatment . Each item of this diary was dichotomised as no (0)=absence of symptom or yes (1)=presence of symptom. The calculation of the Auto-Inflammatory Diseases Activity Index score is straightforward, consisting of the sum of all 12 items (0-372 in a month of 31 days). Higher values represent higher disease activity.
  • 2. Changes in inflammatory markers, including C-reactin protein, erythrocyte sedimentation rate, serum amyloid protein, interleukin-1β and interleukin-18, at 1, 3 and 6 months over baseline [ Time Frame: Baseline and at 1, 3 and 6 months after treatment ]
    C-reactin protein, erythrocyte sedimentation rate, serum amyloid protein, interleukin-1β and interleukin-18 are measured at baseline,1, 3 and 6 months after treatment.
  • 3. Changes in physician global assessment of disease activity on a 0-10 visual analog scale (VAS) at 1, 3 and 6 months over baseline [ Time Frame: Baseline and 1, 3 and 6 months after treatment ]
    Visual analogue scale (VAS) for overall disease activity were completed by the physician at each visit (Baseline and 1, 3 and 6 months after treatment).
  • 4. Changes in parent/patient global assessment of well-being on a 0-10 visual analogue score (VAS) at 1, 3 and 6 months over baseline [ Time Frame: Baseline and 1, 3 and 6 months after treatment ]
    Visual analogue scale (VAS) for overall disease activity were completed by the parent/patient at each visit (Baseline and 1, 3 and 6 months after treatment).
  • 5. Changes in CSF white blood cell count for CINCA patients [ Time Frame: Baseline and 6 months after treatment. ]
    For CINCA patients, Lumbar punctures (LPs) were performed at baseline and 6 months after treatment.
  • 6. Changes in MRI of the brain and inner ear for CINCA patients [ Time Frame: Baseline and 6 months after treatment. ]
    For CINCA patients, MRIs with gadoliniumenhanced fluid-attenuated inversion recovery (FLAIR) sequences of the brain and inner ear were performed and scored at baseline and 6 months after treatment.
  • 7. Changes in audiology data for CINCA patients [ Time Frame: Baseline and 6 months after treatment. ]
    For CINCA patients, Hearing assessment included audiological evaluations. Outcomes in each ear were categorised as 'stable' or 'worsened', according to a modification of the American Speech and Hearing Association (ASHA) criteria, comparing the results at 6 months after treatment over baseline.
  • 8. Number of participants with adverse effect [ Time Frame: Up to 6 months ]
    Treatment-related adverse effect, including abnormal liver function, hematuria and decreased white blood cells
Eligibility Criteria
  • Ages Eligible for Study: (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- All patients must meet the following diagnostic criteria of CAPS and have pathogenic
mutation(s) in NLRP3 gene.

1. Raised inflammatory markers (CRP/SAA) (mandatory criteria)

2. ≥2 of 6 CAPS typical signs/symptoms:

1. Urticaria-like rash;

2. Cold/stress triggered episodes;

3. Sensorineural hearing loss;

4. Musculoskeletal symptoms (arthralgia/arthritis/myalgia);

5. Chronic aseptic meningitis;

6. Skeletal abnormalities (epiphyseal overgrowth/frontal bossing).

Exclusion Criteria:

- Patients will not be included if meets any of the following criteria:

1. Being treated with IL-1 inhibitor, other biological agents and immunosuppressants

2. Pregnant and lactating women

3. Serious organ function failure, expected life time less than 6 months

Contacts and Locations
Contacts

Contact: Hongmei Song, Doctor +86-10-69156271 songhm1021@hotmail.com

Contact: Linqing Zhong +86-13011825185 zhonglinqing_pumch@126.com

Locations

China, Beijing
Peking Union Medical College Hospital
Beijing

Sponsors and Collaborators

Peking Union Medical College Hospital

Investigators

Principal Investigator: Hongmei Song Peking Union Medical College Hospital

More Information
  • Responsible Party: Peking Union Medical College Hospital
  • ClinicalTrials.gov Identifier: NCT03923140 History of Changes
  • Other Study ID Numbers: ZS-1921
  • First Posted: April 22, 2019 Key Record Dates
  • Last Update Posted: June 4, 2019
  • Last Verified: June 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Keywords provided by Peking Union Medical College Hospital: Cryopyrin-Associated Periodic Syndromes
    Tranilast
    Efficacy
    Safety
  • Additional relevant MeSH terms: Cryopyrin-Associated Periodic Syndromes Syndrome